Highlights from the EBMT Annual Meeting / The CAST Strategy for Heavily Pretreated Relapsed/Refractory CNS Lymphoma: A Proof-of-Concept Study

Highlights from the EBMT Annual Meeting / The CAST Strategy for Heavily Pretreated Relapsed/Refractory CNS Lymphoma: A Proof-of-Concept Study

The 52nd EBMT Annual Meeting will be held in Madrid, Spain, from March 22 to 25, 2026. As one of the most prominent international meetings in hematology, EBMT brings together experts worldwide to present advances in hematopoietic stem cell transplantation and cellular therapies, fostering innovation in clinical practice.
Highlights from the EBMT Annual Meeting Impact of the Treatment Sequence of Glofitamab and CAR-T Therapy on Efficacy, Survival, and Target Antigen Expression in Relapsed/Refractory B-NHL 

Highlights from the EBMT Annual Meeting Impact of the Treatment Sequence of Glofitamab and CAR-T Therapy on Efficacy, Survival, and Target Antigen Expression in Relapsed/Refractory B-NHL 

The 52nd EBMT Annual Meeting will take place in Madrid, Spain, from March 22 to 25, 2026. As one of the most influential international meetings in hematopoietic stem cell transplantation and cellular therapy, the congress brings together more than 6,000 experts from over 90 countries and regions to discuss advances in basic research, clinical translation, optimization of transplant strategies, and innovation in cellular therapies.
Voices from China at the EBMT Annual Meeting Prof. Xingyu Cao & Bixin Li: Efficacy and Safety of PD-1 Inhibitors in Acute Leukemia Patients with MRD Positivity After Allogeneic HSCT

Voices from China at the EBMT Annual Meeting Prof. Xingyu Cao & Bixin Li: Efficacy and Safety of PD-1 Inhibitors in Acute Leukemia Patients with MRD Positivity After Allogeneic HSCT

Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the central challenges in the treatment of acute leukemia. Minimal residual disease (MRD) positivity serves as an important early warning signal for relapse, and identifying effective interventions during this critical window has become a major focus of clinical research.
Highlights from the EBMT Annual Meeting CAR-T Alone versus CAR-T Combined with ASCT in Aggressive B-Cell Lymphoma: A Propensity Score–Matched Cohort Study 

Highlights from the EBMT Annual Meeting CAR-T Alone versus CAR-T Combined with ASCT in Aggressive B-Cell Lymphoma: A Propensity Score–Matched Cohort Study 

The 52nd EBMT Annual Meeting was held in Madrid, Spain, from March 22 to 25, 2026. As one of the leading international forums in hematology, the meeting brings together experts worldwide to present advances in transplantation, cellular immunotherapy, and complication management, and remains an important platform shaping the future of hematologic treatment.
EAU26 Afternoon Dialogue | Prof. Peng Zhang: Final Results of the HOPE-03 Study—ADC Plus Immunotherapy Opens a New Era for Bladder Preservation in MIBC

EAU26 Afternoon Dialogue | Prof. Peng Zhang: Final Results of the HOPE-03 Study—ADC Plus Immunotherapy Opens a New Era for Bladder Preservation in MIBC

The 2026 European Association of Urology Annual Congress (EAU26), held in London, brought together leading experts from across the globe to discuss the latest advances in urology. Among the highlights, the final results of the HOPE-03 study, led by Prof. Peng Zhang and his team from West China Hospital, Sichuan University, were presented as an oral session, drawing significant international attention.
ASCO GU On-site Report | Prof. Anna Wilkins: AI Pathology Model MMAI Breaks the Bottleneck in Prostate Cancer Risk Stratification, Unlocking a New Era of Personalized Genitourinary Oncology

ASCO GU On-site Report | Prof. Anna Wilkins: AI Pathology Model MMAI Breaks the Bottleneck in Prostate Cancer Risk Stratification, Unlocking a New Era of Personalized Genitourinary Oncology

During the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), a major breakthrough drew global attention: the first international external validation of the digital pathology–based AI predictive model MMAI in localized prostate cancer. Oncology Frontier – UroStream conducted an on-site interview with Prof. Anna Wilkins, Honorary Consultant in Clinical Oncology at The Institute of Cancer Research and The Royal Marsden Hospital (UK), who provided an in-depth interpretation of the study’s clinical value, real-world implementation prospects, and the broader advances highlighted at this year’s congress.
Voices from China at the EBMT Annual Meeting丨Prof. Yue Lu / Prof. Fang Xu: Efficacy and Safety of Blinatumomab as Part of Induction or Early Consolidation Therapy in Newly Diagnosed B-Cell Acute Leukemia

Voices from China at the EBMT Annual Meeting丨Prof. Yue Lu / Prof. Fang Xu: Efficacy and Safety of Blinatumomab as Part of Induction or Early Consolidation Therapy in Newly Diagnosed B-Cell Acute Leukemia

Blinatumomab, a CD19/CD3 bispecific antibody, has demonstrated clear efficacy in relapsed/refractory and MRD-positive B-cell acute lymphoblastic leukemia (B-ALL). Its integration into frontline therapy for newly diagnosed patients is now being actively explored and may reshape treatment paradigms.
Voices from China at the EBMT Annual Meeting丨Prof. Peihua Lu / Prof. Wei Zhao: Letermovir Prophylaxis Reshapes Early Immune Reconstitution and CMV/EBV Reactivation Dynamics After Allogeneic HSCT

Voices from China at the EBMT Annual Meeting丨Prof. Peihua Lu / Prof. Wei Zhao: Letermovir Prophylaxis Reshapes Early Immune Reconstitution and CMV/EBV Reactivation Dynamics After Allogeneic HSCT

The 52nd EBMT Annual Meeting was held in Madrid, Spain, from March 22 to 25, 2026. As one of the most influential global conferences in hematopoietic stem cell transplantation, the meeting showcased cutting-edge research and the latest clinical advances in the field.
Voices from China at the EBMT Annual Meeting丨Liu Deyan / Liu Xiaohong: Efficacy of Gemtuzumab Ozogamicin in Relapsed/Refractory AML After Allo-HSCT and Outcomes of Bridging to Second/Third Transplantation — A Retrospective Study

Voices from China at the EBMT Annual Meeting丨Liu Deyan / Liu Xiaohong: Efficacy of Gemtuzumab Ozogamicin in Relapsed/Refractory AML After Allo-HSCT and Outcomes of Bridging to Second/Third Transplantation — A Retrospective Study

Relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) carries an extremely poor prognosis, particularly in patients with high CD33 expression who are refractory to conventional salvage therapies, where treatment options remain very limited.
Insights from the EBMT Annual Meeting丨Prof. Yue Lu on Post-Transplant Relapse in Acute Leukemia: Second Transplantation and Donor Optimization Strategies

Insights from the EBMT Annual Meeting丨Prof. Yue Lu on Post-Transplant Relapse in Acute Leukemia: Second Transplantation and Donor Optimization Strategies

Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the major barriers to long-term survival in acute leukemia. With the rapid development of targeted therapies, hypomethylating agents, and immunotherapies such as CAR-T, salvage treatment options have expanded considerably. As a result, more patients are now able to achieve remission again and proceed to subsequent consolidation strategies.